---
document_datetime: 2025-12-02 05:04:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nilotinib-accord.html
document_name: nilotinib-accord.html
version: success
processing_time: 0.1203581
conversion_datetime: 2025-12-25 06:39:26.143413
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nilotinib Accord

[RSS](/en/individual-human-medicine.xml/244581)

##### Authorised

This medicine is authorised for use in the European Union

nilotinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nilotinib Accord](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78750)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Nilotinib Accord is a medicine for treating chronic myelogenous leukaemia (CML) - a blood cancer - in patients who have been newly diagnosed or who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them.

Nilotinib Accord is only for patients with a special chromosome in their cancer cells called the Philadelphia chromosome. Nilotinib Accord is used during the chronic phase of the cancer in adults and children, when the condition is developing slowly and the patient has few or no symptoms. It can also be used in adults during the accelerated phase (when the cancer cells are dividing rapidly and the patient may have more symptoms).

Nilotinib Accord contains the active substance nilotinib and is a 'generic medicine'. This means that Nilotinib Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Nilotinib Accord is Tasigna. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Nilotinib Accord used?

Nilotinib Accord can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of CML.

The medicine is available as capsules to be taken twice a day on an empty stomach. Treatment can continue for as long as the patient benefits from it. Adults whose CML is well controlled may stop treatment but should have regular tests to check that the disease has not started to come back.

For more information about using Nilotinib Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Nilotinib Accord work?

The active substance in Nilotinib Accord, nilotinib, belongs to a group of medicines called 'protein kinase inhibitors'. Nilotinib acts by blocking the protein kinase called BCR-ABL kinase which is produced by leukaemia cells that have the Philadelphia chromosome and causes them to multiply uncontrollably. By blocking BCR-ABL kinase, Nilotinib helps to control the spread of leukaemia cells.

## How has Nilotinib Accord been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Tasigna, and do not need to be repeated for Nilotinib Accord.

As for every medicine, the company provided studies on the quality of Nilotinib Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Nilotinib Accord?

Because Nilotinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Nilotinib Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Nilotinib Accord has been shown to have comparable quality and to be bioequivalent to Tasigna. Therefore, the Agency's view was that, as for Tasigna, the benefits of Nilotinib Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Nilotinib Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nilotinib Accord have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Tasigna also apply to Nilotinib Accord where appropriate.

As for all medicines, data on the use of Nilotinib Accord are continuously monitored. Suspected side effects reported with Nilotinib Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Nilotinib Accord

Nilotinib Accord received a marketing authorisation valid throughout the EU on 22 August 2024.

Nilotinib Accord : EPAR - Medicine overview

Reference Number: EMA/363235/2024

English (EN) (125.64 KB - PDF)

**First published:** 11/09/2024

[View](/en/documents/overview/nilotinib-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-807)

български (BG) (149.77 KB - PDF)

**First published:**

11/09/2024

[View](/bg/documents/overview/nilotinib-accord-epar-medicine-overview_bg.pdf)

español (ES) (127 KB - PDF)

**First published:**

11/09/2024

[View](/es/documents/overview/nilotinib-accord-epar-medicine-overview_es.pdf)

čeština (CS) (146.08 KB - PDF)

**First published:**

11/09/2024

[View](/cs/documents/overview/nilotinib-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (125.55 KB - PDF)

**First published:**

11/09/2024

[View](/da/documents/overview/nilotinib-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (129.4 KB - PDF)

**First published:**

11/09/2024

[View](/de/documents/overview/nilotinib-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.76 KB - PDF)

**First published:**

11/09/2024

[View](/et/documents/overview/nilotinib-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.45 KB - PDF)

**First published:**

11/09/2024

[View](/el/documents/overview/nilotinib-accord-epar-medicine-overview_el.pdf)

français (FR) (127.83 KB - PDF)

**First published:**

11/09/2024

[View](/fr/documents/overview/nilotinib-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.05 KB - PDF)

**First published:**

11/09/2024

[View](/hr/documents/overview/nilotinib-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (125.04 KB - PDF)

**First published:**

11/09/2024

[View](/it/documents/overview/nilotinib-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.48 KB - PDF)

**First published:**

11/09/2024

[View](/lv/documents/overview/nilotinib-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (147.82 KB - PDF)

**First published:**

11/09/2024

[View](/lt/documents/overview/nilotinib-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (148.16 KB - PDF)

**First published:**

11/09/2024

[View](/hu/documents/overview/nilotinib-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (148.68 KB - PDF)

**First published:**

11/09/2024

[View](/mt/documents/overview/nilotinib-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (126.21 KB - PDF)

**First published:**

11/09/2024

[View](/nl/documents/overview/nilotinib-accord-epar-medicine-overview_nl.pdf)

polski (PL) (150.67 KB - PDF)

**First published:**

11/09/2024

[View](/pl/documents/overview/nilotinib-accord-epar-medicine-overview_pl.pdf)

português (PT) (127.18 KB - PDF)

**First published:**

11/09/2024

[View](/pt/documents/overview/nilotinib-accord-epar-medicine-overview_pt.pdf)

română (RO) (144.68 KB - PDF)

**First published:**

11/09/2024

[View](/ro/documents/overview/nilotinib-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (146.76 KB - PDF)

**First published:**

11/09/2024

[View](/sk/documents/overview/nilotinib-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.85 KB - PDF)

**First published:**

11/09/2024

[View](/sl/documents/overview/nilotinib-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (124.17 KB - PDF)

**First published:**

11/09/2024

[View](/fi/documents/overview/nilotinib-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (125.23 KB - PDF)

**First published:**

11/09/2024

[View](/sv/documents/overview/nilotinib-accord-epar-medicine-overview_sv.pdf)

Nilotinib Accord : EPAR - Risk management plan

English (EN) (1.56 MB - PDF)

**First published:** 11/09/2024

[View](/en/documents/rmp/nilotinib-accord-epar-risk-management-plan_en.pdf)

## Product information

Nilotinib Accord : EPAR - Product information

English (EN) (887.37 KB - PDF)

**First published:** 11/09/2024

**Last updated:** 27/08/2025

[View](/en/documents/product-information/nilotinib-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-366)

български (BG) (1.04 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/bg/documents/product-information/nilotinib-accord-epar-product-information_bg.pdf)

español (ES) (971.72 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/es/documents/product-information/nilotinib-accord-epar-product-information_es.pdf)

čeština (CS) (1.01 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/cs/documents/product-information/nilotinib-accord-epar-product-information_cs.pdf)

dansk (DA) (986.77 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/da/documents/product-information/nilotinib-accord-epar-product-information_da.pdf)

Deutsch (DE) (885.87 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

11/09/2025

[View](/de/documents/product-information/nilotinib-accord-epar-product-information_de.pdf)

eesti keel (ET) (907.25 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/et/documents/product-information/nilotinib-accord-epar-product-information_et.pdf)

ελληνικά (EL) (1.08 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/el/documents/product-information/nilotinib-accord-epar-product-information_el.pdf)

français (FR) (1.03 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/fr/documents/product-information/nilotinib-accord-epar-product-information_fr.pdf)

hrvatski (HR) (1017.89 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/hr/documents/product-information/nilotinib-accord-epar-product-information_hr.pdf)

íslenska (IS) (993.99 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/is/documents/product-information/nilotinib-accord-epar-product-information_is.pdf)

italiano (IT) (942.19 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/it/documents/product-information/nilotinib-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (980.59 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/lv/documents/product-information/nilotinib-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.06 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/lt/documents/product-information/nilotinib-accord-epar-product-information_lt.pdf)

magyar (HU) (852.53 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/hu/documents/product-information/nilotinib-accord-epar-product-information_hu.pdf)

Malti (MT) (1.19 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/mt/documents/product-information/nilotinib-accord-epar-product-information_mt.pdf)

Nederlands (NL) (1013.3 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/nl/documents/product-information/nilotinib-accord-epar-product-information_nl.pdf)

norsk (NO) (995.73 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/no/documents/product-information/nilotinib-accord-epar-product-information_no.pdf)

polski (PL) (1021.28 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/pl/documents/product-information/nilotinib-accord-epar-product-information_pl.pdf)

português (PT) (1.01 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/pt/documents/product-information/nilotinib-accord-epar-product-information_pt.pdf)

română (RO) (1.03 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/ro/documents/product-information/nilotinib-accord-epar-product-information_ro.pdf)

slovenčina (SK) (1.05 MB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/sk/documents/product-information/nilotinib-accord-epar-product-information_sk.pdf)

slovenščina (SL) (1004.13 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/sl/documents/product-information/nilotinib-accord-epar-product-information_sl.pdf)

Suomi (FI) (987.26 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/fi/documents/product-information/nilotinib-accord-epar-product-information_fi.pdf)

svenska (SV) (978.92 KB - PDF)

**First published:**

11/09/2024

**Last updated:**

27/08/2025

[View](/sv/documents/product-information/nilotinib-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000291910 26/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nilotinib Accord : EPAR - All authorised presentations

English (EN) (91.27 KB - PDF)

**First published:** 11/09/2024

[View](/en/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-806)

български (BG) (101.94 KB - PDF)

**First published:**

11/09/2024

[View](/bg/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (90.95 KB - PDF)

**First published:**

11/09/2024

[View](/es/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (94.02 KB - PDF)

**First published:**

11/09/2024

[View](/cs/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (92.76 KB - PDF)

**First published:**

11/09/2024

[View](/da/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (97.07 KB - PDF)

**First published:**

11/09/2024

[View](/de/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (91.04 KB - PDF)

**First published:**

11/09/2024

[View](/et/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (98.39 KB - PDF)

**First published:**

11/09/2024

[View](/el/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (92.73 KB - PDF)

**First published:**

11/09/2024

[View](/fr/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (94.34 KB - PDF)

**First published:**

11/09/2024

[View](/hr/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (92.79 KB - PDF)

**First published:**

11/09/2024

[View](/is/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (94.16 KB - PDF)

**First published:**

11/09/2024

[View](/it/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (96.24 KB - PDF)

**First published:**

11/09/2024

[View](/lv/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (97.02 KB - PDF)

**First published:**

11/09/2024

[View](/lt/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (96.74 KB - PDF)

**First published:**

11/09/2024

[View](/hu/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (95.73 KB - PDF)

**First published:**

11/09/2024

[View](/mt/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (91.48 KB - PDF)

**First published:**

11/09/2024

[View](/nl/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (92.87 KB - PDF)

**First published:**

11/09/2024

[View](/no/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (94.33 KB - PDF)

**First published:**

11/09/2024

[View](/pl/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (94.96 KB - PDF)

**First published:**

11/09/2024

[View](/pt/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (93.93 KB - PDF)

**First published:**

11/09/2024

[View](/ro/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (93.79 KB - PDF)

**First published:**

11/09/2024

[View](/sk/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (93.21 KB - PDF)

**First published:**

11/09/2024

[View](/sl/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (91.54 KB - PDF)

**First published:**

11/09/2024

[View](/fi/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (92.59 KB - PDF)

**First published:**

11/09/2024

[View](/sv/documents/all-authorised-presentations/nilotinib-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nilotinib Accord Active substance nilotinib International non-proprietary name (INN) or common name nilotinib Therapeutic area (MeSH) Leukemia, Myelogenous, Chronic, BCR-ABL Positive Anatomical therapeutic chemical (ATC) code L01EA03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Nilotinib Accord is indicated for the treatment of:

- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,

- adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,

- paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

## Authorisation details

EMA product number EMEA/H/C/006315

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 27/06/2024 Marketing authorisation issued 22/08/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nilotinib Accord : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (154.76 KB - PDF)

**First published:** 23/04/2025

**Last updated:** 27/08/2025

[View](/en/documents/procedural-steps-after/nilotinib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Nilotinib Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/325502/2024

English (EN) (737.6 KB - PDF)

**First published:** 11/09/2024

[View](/en/documents/assessment-report/nilotinib-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nilotinib Accord

Adopted

Reference Number: EMA/CHMP/281252/2024

English (EN) (129.34 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nilotinib-accord_en.pdf)

#### News on Nilotinib Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Nilotinib Accord : EPAR - Product information - tracked changes

English (EN) (471.49 KB - DOCX)

**First published:** 27/08/2025

[View](/en/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-976)

български (BG) (814.49 KB - DOCX)

**First published:**

27/08/2025

[View](/bg/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (801 KB - DOCX)

**First published:**

27/08/2025

[View](/es/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (732.48 KB - DOCX)

**First published:**

27/08/2025

[View](/cs/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (797.41 KB - DOCX)

**First published:**

27/08/2025

[View](/da/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (804.62 KB - DOCX)

**First published:**

27/08/2025

[View](/de/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (417.74 KB - DOCX)

**First published:**

27/08/2025

[View](/et/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (484.31 KB - DOCX)

**First published:**

27/08/2025

[View](/el/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (817.87 KB - DOCX)

**First published:**

27/08/2025

[View](/fr/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (798.03 KB - DOCX)

**First published:**

27/08/2025

[View](/hr/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (751.03 KB - DOCX)

**First published:**

27/08/2025

[View](/is/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (769.84 KB - DOCX)

**First published:**

27/08/2025

[View](/it/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (777.57 KB - DOCX)

**First published:**

27/08/2025

[View](/lv/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (776.77 KB - DOCX)

**First published:**

27/08/2025

[View](/lt/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (736.87 KB - DOCX)

**First published:**

27/08/2025

[View](/hu/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (767.36 KB - DOCX)

**First published:**

27/08/2025

[View](/mt/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (779.04 KB - DOCX)

**First published:**

27/08/2025

[View](/nl/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (800.41 KB - DOCX)

**First published:**

27/08/2025

[View](/no/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (791.87 KB - DOCX)

**First published:**

27/08/2025

[View](/pl/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (743.6 KB - DOCX)

**First published:**

27/08/2025

[View](/pt/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (793.37 KB - DOCX)

**First published:**

27/08/2025

[View](/ro/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (744.79 KB - DOCX)

**First published:**

27/08/2025

[View](/sk/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (771.61 KB - DOCX)

**First published:**

27/08/2025

[View](/sl/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (783.61 KB - DOCX)

**First published:**

27/08/2025

[View](/fi/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (770.54 KB - DOCX)

**First published:**

27/08/2025

[View](/sv/documents/product-information-tracked-changes/nilotinib-accord-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 11/09/2025

## Share this page

[Back to top](#main-content)